2,293
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Upregulation of miRNA-10a-5p promotes tumor progression in cervical cancer by suppressing UBE2I signaling

ORCID Icon, , , , , & ORCID Icon show all
Article: 2171283 | Received 05 Dec 2022, Accepted 18 Jan 2023, Published online: 06 Feb 2023

References

  • Alarcón, C.R., et al., 2015. N6-methyladenosine marks primary microRNAs for processing. Nature, 519 (7544), 482–485.
  • Bhaskaran, M. and Mohan, M., 2014. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Veterinary Pathology, 51 (4), 759–774.
  • Bizzarri, N., et al., 2021a. Peritoneal HPV-DNA test in cervical cancer (PIONEER study): a proof of concept. International Journal of Cancer, 148 (5), 1197–1207.
  • Bizzarri, N., et al., 2021b. Protective role of conization before radical hysterectomy in early-stage cervical cancer: a propensity-score matching study. Annals of Surgical Oncology, 28 (7), 3585–3594.
  • Casarin, J., et al., 2021. Preoperative conization and risk of recurrence in patients undergoing laparoscopic radical hysterectomy for early stage cervical cancer: a multicenter study. Journal of Minimally Invasive Gynecology, 28 (1), 117–123.
  • Cascardi, E., et al., 2022. Association between cervical microbiota and HPV: could this be the key to complete cervical cancer eradication? Biology, 11 (8), 1114.
  • Cox, A.R., et al., 2021. Ube2i deletion in adipocytes causes lipoatrophy in mice. Molecular Metabolism, 48, 101221.
  • Dellino, M., et al., 2022a. Lactobacillus crispatus M247 oral administration: is it really an effective strategy in the management of papillomavirus-infected women? Infectious Agents and Cancer, 17 (1), 53.
  • Dellino, M., et al., 2022b. Communications is time for care: an Italian monocentric survey on human papillomavirus (HPV) risk information as part of cervical cancer screening. Journal of Personalized Medicine, 12 (9), 1387.
  • D’Oria, O., et al., 2022. New advances in cervical cancer: from bench to bedside. International Journal of Environmental Research and Public Health., 19 (12), 7094.
  • Fabian, M.R., Sonenberg, N., and Filipowicz, W., 2010. Regulation of mRNA translation and stability by microRNAs. Annual Review of Biochemistry, 79, 351–379.
  • Giannini, A., et al., 2022. Advances on prevention and screening of gynecologic tumors: are we stepping forward? Healthcare, 10 (9), 1605.
  • Guo, Y., et al., 2012. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncology Reports, 27 (1), 286–292.
  • He, W.Q. and Li, C., 2021. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecologic Oncology, 163 (3), 583–592.
  • Huang, Z., et al., 2021. Prognostic significance and tumor immune microenvironment heterogenicity of m5C RNA methylation regulators in triple-negative breast cancer. Frontiers in Cell and Developmental Biology, 9, 657547.
  • Ihara, M., Stein, P., and Schultz, R.M., 2008. UBE2I (UBC9), a SUMO-conjugating enzyme, localizes to nuclear speckles and stimulates transcription in mouse oocytes. Biology of Reproduction, 79 (5), 906–913.
  • Kietpeerakool, C., et al., 2019. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). The Cochrane Database of Systematic Reviews, 2 (2), Cd012828.
  • Koch, A., et al., 2018. Analysis of DNA methylation in cancer: location revisited. Nature Reviews. Clinical Oncology, 15 (7), 459–466.
  • Li, X. and Meng, Y., 2021. SUMOylation regulator-related molecules can be used as prognostic biomarkers for glioblastoma. Frontiers in Cell and Developmental Biology, 9, 658856.
  • Liu, Y., et al., 2017. miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis. Cell Death & Disease, 8 (4), e2739.
  • Long, M.J., et al., 2012. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Letters, 324 (2), 186–196.
  • Lu, A., et al., 2021. Aim2 couples with Ube2i for sumoylation-mediated repression of interferon signatures in systemic lupus erythematosus. Arthritis & Rheumatology, 73 (8), 1467–1477.
  • Marima, R., et al., 2021. MicroRNA and alternative mRNA splicing events in cancer drug response/resistance: potent therapeutic targets. Biomedicines, 9 (12), 1818.
  • Meng, Y. and Li, X., 2021. Expression and prognosis analysis of SUMOylation regulators in oral squamous cell carcinoma based on high-throughput sequencing. Frontiers in Genetics, 12, 671392.
  • Mezei, A.K., et al., 2017. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. International Journal of Cancer, 141 (3), 437–446.
  • Saliminejad, K., et al., 2019. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. Journal of Cellular Physiology, 234 (5), 5451–5465.
  • Schee, K., et al., 2013. Deep sequencing the microRNA transcriptome in colorectal cancer. PLoS One, 8 (6), e66165.
  • Sommerova, L., et al., 2019. The role of miR-409-3p in regulation of HPV16/18-E6 mRNA in human cervical high-grade squamous intraepithelial lesions. Antiviral Research, 163, 185–192.
  • Szalmás, A. and Kónya, J., 2009. Epigenetic alterations in cervical carcinogenesis. Seminars in Cancer Biology, 19 (3), 144–152.
  • Thomou, T., et al., 2017. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature, 542 (7642), 450–455.
  • Torre, L.A., et al., 2015. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65 (2), 87–108.
  • Valenti, G., et al., 2017. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates in Surgery, 69 (4), 441–449.
  • Villanueva, L., Álvarez-Errico, D., and Esteller, M., 2020. The contribution of epigenetics to cancer immunotherapy. Trends in Immunology, 41 (8), 676–691.
  • Waggoner, S.E., 2003. Cervical cancer. Lancet, 361, 2217–2225.
  • Wang, R., et al., 2020. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Letters, 471, 88–102.
  • Worst, T.S., et al., 2019. miR-10a-5p and miR-29b-3p as extracellular vesicle-associated prostate cancer detection markers. Cancers, 12 (1), 43.
  • Yang, H., et al., 2020. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma. Cancer Cell International, 20, 234.
  • Yang, L., et al., 2021. MiR-10a-5p: a promising biomarker for early diagnosis and prognosis evaluation of bladder cancer. Cancer Management and Research, 13, 7841–7850.
  • Zhai, L., et al., 2017. MicroRNA-10a-5p suppresses cancer proliferation and division in human cervical cancer by targeting BDNF. Experimental and Therapeutic Medicine, 14 (6), 6147–6151.
  • Zhang, Y., et al., 2018. Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer. Cell Death & Disease, 9 (3), 301.
  • Zhang, X., et al., 2021. Extracellular vesicles-encapsulated microRNA-10a-5p shed from cancer-associated fibroblast facilitates cervical squamous cell carcinoma cell angiogenesis and tumorigenicity via Hedgehog signaling pathway. Cancer Gene Therapy, 28 (5), 529–542.
  • Zhi, F., et al., 2013. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One, 8 (2), e56718.